



SciCafe

Nature SciCafe Asia

— Biotech Science & Investment Forum —

**MONDAY, 24 OCTOBER 2016 AT DUKE-NUS MEDICAL SCHOOL, AMPHITHEATRE,
SINGAPORE**

Welcome to the Nature SciCafe Asia 2016. Nature SciCafe Asia is an invitation-only biotech forum for investors, entrepreneurs, scientists, government agencies and industry representatives. Only in its second run, the forum has grown to be a series of biotech sessions that aims to develop a strong biotech investment environment in Asia, and connect rising stars in biomedical research to regional investment communities.

In the forum, top biomedical investigators, handpicked by *Nature Biotechnology* and *Nature Medicine*, will speak of their translational and druggable work. These investigators have been chosen to present their cutting-edge work based on their scientific excellence and on the potential commercial interest of their research to an investor audience.

Not forgetting the opportunity to network with influential scientists, investors as well as key representatives from academic institutions, pharmaceutical companies and government officials from the Asia Pacific region.

This year's theme for the panel sessions are on 'How policies drive innovation in BioMedicine' - where we are joined by guest speakers from the pharmaceutical industry and various government officials from around the region.

I would also like to extend my heartfelt appreciation to the following people and organisations; Dr. Marshall (*Nature Biotechnology*) for the collaboration and to Profs Epstein (Duke-NUS) and Mynt (A*Star) for their valuable contribution. I would also like to thank our partner and sponsors who have contributed greatly to the event (NUHS, Menarini Biomarkers, National Research Foundation of Singapore and Johnson & Johnson Innovation) and to the speakers and panelists for their participation.

To our attendees, thank you for joining us. I hope that all of you will not only have a great experience at the Nature SciCafe Asia 2016 but benefit greatly from it.

Warmest regards,

Salvatore Albani, M.D., Ph.D.
Director, SingHealth Translational Immunology and Inflammation Centre Senior Clinical
Professor, Duke-NUS Graduate Medical School
Senior Clinical Scientist, Paediatrics Academic Clinical Program

ORGANISING COMMITTEE

Professor Salvatore Albani, Professor at Duke-NUS Graduate Medical School Singapore, Director of the SingHealth Translational Immunology & Inflammation Centre, and Senior Clinical Scientist with the Paediatrics Academic Clinical Program.

Dr. David M. Epstein, Associate Professor, Associate Dean and Director of the Centre for Technology & Development (CTeD) at Duke-NUS Graduate Medical School in Singapore.

Professor Steven Myint, physician with global experience in health & biomedical management. Currently a Senior fellow to A*star & consultant to its commercialisation arm, ETPL.

Mr. Estar Rino, Project Manager, SingHealth Translational Immunology and Inflammation Centre.

Ms. Julia Ong, Executive Manager, Eureka Institute for Translational Medicine.

SPECIAL ACKNOWLEDGEMENT

Dr. Lakshmi Ramakrishna, Ms Tricia Wang and Ms Maureen Knights, SingHealth Translational Immunology & Inflammation Centre.

Ms Shanti Rajaram, Secretary to Associate Prof David M. Epstein, Associate Dean, Office of Research and Director, Center for Technology & Development, Duke-NUS Medical School.

SingHealth Office of Research.



VENUE DETAILS



DAY LOCATION:

Amphitheatre, Duke-NUS Medical School Singapore | 8 College Road, Singapore 169857

EVENING LOCATION:

Level 3, The Academia | 20 College Road, Singapore 169856

PARKING:

	Multi-storey & Open Space Carpark (MSCP) H	National Heart Centre (NHCS)
Location	End of MacAlister Road. Both multi-storey Carpark and Open Space Carpark are located behind Ministry of Health (MOH).	5 Hospital Drive, opposite SGH Block 4
Parking charges	Weekdays (7am - 9.59pm): S\$0.018 per minute/S\$1.08 per hour. Weekdays (10pm - 6.59am): S\$2.14 per entry.	Weekdays (7am - 9.59pm): S\$0.036 per minute/S\$2.16 per hour. Weekdays (10pm - 6.59am): S\$2.10 per entry.

* Due to limited parking lots, driving is not recommended.

2016 PROGRAMME

TIME	ITEM	BY
7:30 am	Registration opens	-
7:30 - 8:30 am	Breakfast	-
8:45 - 9:00 am	Welcome address	Professor Salvatore Albani
9:00 - 9:15 am	Introductory address by <i>Nature Biotechnology</i>	Dr. Andrew Marshall
9:15 - 9:30 am	Patients: At the heart of all we do	Dr. Vicki Seyfert-Margolis
9:30 - 11:30 am	<p>PART I: HOW POLICIES DRIVE INNOVATION IN BIOMEDICINE</p> <p>Government's vision and strategies; Evolving balance between basic and translational research</p> <p><i>- Representatives from government agencies: Outlining policies and choices</i></p>	<p>Moderator: Professor David Epstein</p> <p>Panelists:</p> <ol style="list-style-type: none"> 1. Australia - Dr. Christine William 2. India - Dr. Taslimarif Saiyed 3. Japan - Mr. Yutaka Hishuyama 4. South Korea - Mr. Jee-Young Yoon 5. Singapore - Dr. Pauline Tay
11:30 am - 12:00 pm	Morning coffee break	-
12:00 - 12:20 pm	Selected Presentation I: Error-correction code fluorogenic DNA sequencing	Professor Yanyi Huang
12:20 - 12:40 pm	Selected Presentation II: Soft Electronics in Medicine - Sweat-based diabetes treatment system	Associate Professor Dae-Hyeong Kim
12:40 - 1:00 pm	Selected Presentation III: Designing biomaterials for cell transplantation in diabetes	Associate Professor Ying Luo
1:00 - 2:00 pm	Lunch	-
2:00 - 2:20 pm	Selected Presentation IV: Artificial Tissues	Dr. Ng Shyh-Chang
2:20 - 2:40 pm	Selected Presentation V: Innatotherapy - manipulating innate immunity to combat infectious diseases	Associate Professor Matt Sweet
2:40 - 3:00 pm	Selected Presentation VI: Stapled Diets in Biology promise reagents and therapies	Dr. Chandra Verma
3:00 - 3:30 pm	Afternoon coffee break	-
3:30 - 5:30 pm	<p>PART II: HOW POLICIES DRIVE INNOVATION IN BIOMEDICINE</p> <p>Pharma's vision and strategies; Evolving balance between basic and translational research</p> <p><i>- Representatives from pharmaceutical companies: Outlining relationships, partnerships and expectations</i></p>	<p>Moderator: Dr Ken Noonan (Lightstone)</p> <p>Panelists:</p> <ol style="list-style-type: none"> 1. GSK - Dr. Philippe Buchy 2. J&J Innovation - Mr. Dong Wu 3. Menarini Biomarkers - Mr. Luigi Ricciardi
5:30 - 5:45 pm	Summary and closing session	Professor Steve Myint
5:45 - 6:00 pm	Networking session	-
6:00 - 10:00 pm	Dinner at SingHealth Academia, Level 3	-

SELECTED PRESENTATIONS

SELECTED PRESENTATION I

Speaker: Dr. Yanyi Huang

Title: Error-correction code fluorogenic DNA sequencing

Synopsis: It is critical but challenging to identify or remove errors in the sequencing reads generated by next generations DNA sequencers. We have developed a new sequencing method, error-correction code (ECC) sequencing, that employs a unique dual-base flowgram and show that with no extra consumption of reaction time, or cycle numbers, ECC sequencing approach can provide single-end error-free sequences up to 250 bp in our lab prototype.

SELECTED PRESENTATION II

Speaker: Associate Professor Dae-Hyeong Kim

Title: Soft Electronics in Medicine - Sweat-based diabetes treatment system

Synopsis: Recent progresses in the sweat-based glucose sensing system integrated with a feedback transdermal drug delivery module. The sweat-based sensing provides a user-friendly, painless, and stress-free method for the glucose monitoring. The nanomaterials-based integrated sensor array maximizes accuracy as well as sensitivity of the glucose measurement from the sweat. Appropriate delivery of medications through the skin with the microneedles successfully controls the glucose concentration.

SELECTED PRESENTATION III

Speaker: Associate Professor Ying Luo

Title: Designing biomaterials for cell transplantation in diabetes

Synopsis: Transplantation of therapeutic cells represents an important regenerative strategy for treating diabetes. Two types of biomaterials were fabricated with microstructural characteristics based on electrospun fibers and decellularized matrices and the in vivo experiments in diabetic rodents showed the function of these materials to effectively support the engraftment of islets/mesenchymal stem cells to reverse the hyperglycemic condition.

SELECTED PRESENTATION IV

Speaker: Dr. Ng Shyh-Chang

Title: Artificial Tissues

Synopsis: In my talk I will discuss how it is now possible, with metabolic engineering, to mass-produce artificial tissues derived from human stem cells, including mature human muscles. Combined with big data omics analysis, our platform technology could dramatically improve the modelling of human disease conditions, such as cancer cachexia, and significantly increase the odds of success for novel drug discovery.

SELECTED PRESENTATION V

Speaker: Associate Professor Matt Sweet

Title: Innatotherapy - manipulating innate immunity to combat infectious diseases

Synopsis: I study danger sensing pattern recognition receptors of innate immunity, such as the Toll-like receptors, and their roles in infectious and inflammatory diseases. In this presentation, I will outline a strategy for manipulating Toll-like Receptor-regulated innate immune responses as an anti-infective approach for combating infectious diseases caused by bacterial pathogens.

SELECTED PRESENTATION VI

Speaker: Dr. Chandra Verma

Title: Stapled Diets in Biology promise reagents and therapies

Synopsis: Discussions will be carried out on how the ability to probe interactions in/between cells with reduced costs and high specificity opens possibilities of new reagents and a new class of medicines.


BIOGRAPHIES OF SPEAKERS, MODERATORS AND PANELISTS

SPEAKERS



Professor Salvatore Albani, Professor at Duke-NUS Graduate Medical School Singapore, Director of the SingHealth Translational Immunology & Inflammation Centre, and Senior Clinical Scientist with the Paediatrics Academic Clinical Program. Professor Albani is an internationally renowned rheumatologist and immunologist. His fundamental research interest is in understanding human immunity and contributing the knowledge to therapeutic and diagnostic advancements. He developed several innovative approaches in the area of induction and maintenance of immune tolerance in humans, being responsible for the whole translational process from idea to conclusion of Phase II clinical trial in autoimmune inflammatory diseases, which have a large impact on society and individuals. This translational research itinerary has been the original backbone of his career, as witnessed by a rich publication trail (among others *Nature Medicine*, *Lancet*, *JCI*, *PNAS*, *Nature Rheumatology*, *A&R*, *ARD*, etc) and by approximately 100 patents, disclosures and applications.

Dr. Min Cho is a senior editor and team manager (life sciences) of *Nature Communications* where he manages the selection of original research manuscripts for publication. He became a scientific editor with *Nature Neuroscience* in late 2007, and joined the *Nature Communications* editorial team in June 2015. He received his doctorate degree in molecular biology and neuroscience from Princeton University where he investigated the molecular mechanisms underlying mammalian learning and memory processes. Using genetic engineering techniques in mice, he continued this work at Boston University. Prior to his formal training, he coordinated a clinical and academic research program at the Cardiovascular Research Institute at the University of California, San Francisco on projects concerning genetic and molecular basis of cardiovascular diseases and lipid/cholesterol disorders. Prior to his non-neuroscience stint at UCSF, he received an undergraduate training in neuroscience from New York University, Center for Neural Science and received Bachelor of Science degree in 1997. Dr. Min is based at the Springer Nature's Shanghai office.





Dr. Yanyi Huang received his BS (Chemistry) and ScD (Inorganic Chemistry) degrees from Peking University in 1997 and 2002, respectively. He then conducted his postdoc research at Caltech (Applied Physics, 2002-2005) and Stanford (Bioengineering, 2005-2006). He started his independent career at Peking University in 2006 as a Principal Investigator and then promoted to Associate Professor in 2009, and Professor in 2013. He is Professor of Materials Science and Engineering, PI in Biodynamic Optical Imaging Center (BIOPIC), PI in Peking-Tsinghua Center for Life Sciences, PI in Beijing Advanced Innovation Center for Genomics, and an Adjunct Professor of Analytical Chemistry. His research interests are single cell analysis, sequencing technologies, and microscopic imaging.

Website: <http://biopic.pku.edu.cn/english/detail.aspx?id=2>

Associate Professor Dae-Hyeong Kim is an Associate Professor for Seoul National University. He completed his senior postdoc from John Rogers lab at University of Illinois. Kim is one of the world's authorities on flexible electronics for skin-mounted biomedical devices and electronic skin for prosthetic limbs. This is an area where Korea may lead the world, given the close ties with Samsung. Numerous pubs in recent years (Science 333, 838 (2011) and Nature Nanotechnology 9, 397 (2014), Advanced Healthcare Materials AOP (2015); Nature Communications 5, 5747 (2014). He will discuss his June paper in Nature Nanotech describing a stretchable gold/grapheme device combining temperature, humidity, glucose and pH sensors with polymeric microneedles for delivery of metformin in a diabetes model.



Website: flextronics.snu.ac.kr



Dr. Ying Luo is an Associate Professor of the Department of Biomedical Engineering at Peking University. Dr. Ying Luo received a B.S. in chemistry from Peking University in 1997. She obtained a Ph.D. from the University of Toronto in Canada and conducted her postdoctoral research at the Massachusetts Institute of Technology before taking the faculty position at Peking University since 2007. The primary focus of Dr. Luo's laboratory is to integrate the knowledge in material science, biology and medicine to develop new biomaterials and devices for medical uses.

In particular, Dr. Luo is interested in investigating the fundamental design principles of bioactive materials for tissue regeneration and fabrication/engineering of cell-transplantation devices and RNA-delivery vehicles for clinical applications. The research of Dr. Luo's laboratory is conducted at molecular, cellular and animal levels, and the new biomaterials/devices developed by her team are assessed for therapeutic

applications in treating heart infarction and diabetes. Dr. Luo has so far authored over 20 scientific papers and holds four invention patents. Dr. Luo was awarded Outstanding Young Scholar from the National Natural Science Foundation of China in 2013 and served as Vice Director of National Engineering Laboratory of Implantable and Regenerative Devices (2011-2013).

Website: <http://en.coe.pku.edu.cn/Faculty-A-Z/45.htm>



Dr. Andrew Marshall has been Chief Editor of *Nature Biotechnology* since 2000. Since that time, the journal's impact factor has increased from 11.0 to 43.1. It is currently among the top 10 primary research journals in the world. As well as frequently speaking on biotechnology issues at international meetings, he also regularly heads and organises conferences and symposia for the journal. He has over 24 years of experience in scientific publishing, and was previously Editor of *Current Opinion in Biotechnology* from 1992 to 1996. He has written over 150 articles and editorials on science and technology for the popular media, including *The Economist* and *Popular Science*, and for trade publications. In 2003, he launched *Bioentrepreneur* (www.nature.com/bioent), a free web portal that provides didactic information and advice to aspiring entrepreneurs seeking to start biotech companies. He also runs a series of networking events (SciCafes) in Boston, New York, San Francisco, San Diego, Houston, London and Singapore to promote pioneering translational work by junior faculty. He is currently a Voluntary Professor of Biochemistry and Molecular Biology at the University of Miami. He obtained his PhD and postdoctoral experience in molecular biology and microbiology at King's College London and is the recipient of the Helen White Prize.

Professor Steven Myint is a physician with global experience in health & biomedical management. He is currently a Senior fellow to A*STAR, and consultant to its commercialization arm, ETPL. He is also Adjunct Professor at Duke-NUS in the Center for Technology, Enterprise and Development. In these capacities he is involved in the commercialisation of biomedical and bio-engineering research. He is also Chairman of Inex Private Ltd. In Finland he is chairman of Plexpress Oy and Inc, a diagnostic technology company with a US subsidiary and non-executive director of Aplagon Oy and Primex Oy, both biotech companies. In the US he is a non-executive director of Lipid Genomics, a diagnostic company spun out of Johns Hopkins, now based in Boston. He was also founding partner of a Finnish Vigo accelerator, Ukko Partners. In addition he is a partner in several investment funds. Until recently he was also executive chairman of Green Signal Bio, which he developed into one of India's largest vaccine manufacturers. After his own first university spinout in 1995, he has been involved in the development of over 30 SME's in life sciences and created over \$1billion value for shareholders.





Associate Professor Ng Shyh-Chang, Principal Investigator, A*STAR and NUS. An alumnus of George Daley and Lewis Cantley's labs at Harvard Medical School. He's been using big data technologies to dissect aging, degeneration and regeneration. Applying their in-house genomics, metabolomics, and artificial muscle technologies to a chronic degenerative syndrome called cachexia, he recently published a paper in *Nature Medicine* (May 2016) that implicated excessive fatty acid oxidation (FAO) as the cause for terminal weight loss in advanced cancer patients. A novel formulation of an FAO inhibitor drug rescued the lethal weight loss in several preclinical models of cachexia. A patent has been filed under A*STAR and

the National Cancer Centre to cover these discoveries. He will also briefly discuss his latest artificial muscle technology, and how it can be applied to other diseases of aging. In his youth, he won the Gold Medal at the International Biology Olympiad. He graduated with an A.B. *summa cum laude* from Princeton University in 3 years, and completed his Ph.D. at Harvard Medical School. There he served as Chairman of the Harvard Biotechnology Society, co-founded the HBS Consulting group, and served as the youngest member of the Massachusetts Life Sciences Startup Initiative's 10-person committee.

Website: www.skmusclelab.com

Dr. Vicki Seyfert-Margolis is CEO and Founder of My Own Med Inc. Founded My Own Med in January 2013, based on over two years of work on a database, web and mobile application platform technology for family based co-management of health. Previously, she was the Senior Advisor for Science Innovation and Policy in the Office of the Commissioner of the US Food and Drug Administration. While at the FDA, she oversaw the development and execution of an agency wide strategic plan for regulatory science. Prior to the FDA, she served as Chief Scientific Officer at the Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, she oversaw the development of over 20 leading edge assay development and centralised laboratory facilities, bringing them to GLP and CLIA compliance. She designed and implemented biomarker discovery studies for over 25 Phase II clinical trials across a broad array of immunologically mediated diseases including autoimmune disorders, allergy, and solid organ transplantation. Dr. Seyfert-Margolis completed her PhD in immunology at the University of Pennsylvania's School of Medicine, and her post-doctoral fellowship work at Harvard University and the National Cancer Institute.





Associate Professor Matthew Sweet, is an Associate Professor of the Institute for Molecular Bioscience (IMB), University of Queensland. Associate Professor Matt Sweet studies the role of the innate immune system in infectious and inflammatory disease processes. His major research focus is on the control of macrophage functions by pattern recognition receptors, such as the Toll-like receptors and inflammasome-forming Nod-like receptors. These receptors sense and respond to danger in the form of infection, cell damage and/or dysregulated metabolism. He is researching the roles of pattern recognition receptors and downstream signaling pathways in macrophage responses during infections caused by Gram-negative bacterial pathogens such as *Salmonella* and uropathogenic *E. coli*, and during chronic inflammatory diseases such as liver fibrosis.

Website: www.imb.uq.edu.au/matt-sweet

Dr. Chandra Verma is the Head of Division of Biomolecular Modelling and Design, Bioinformatics Institute (BII) A*STAR. He joined the Bioinformatics Institute (BII) A*STAR, Singapore, in November 2003. He heads the division of Biomolecular Modelling and Design and leads a group that applies physics based models to understand the links between protein sequence, structure and biological function. His group works closely with experimental laboratories where the hypotheses generated are tested. In addition, the group is also involved in designing peptides and small molecules (through virtual screening) both for interrogating biology as well as for therapeutic purposes. Prior to working in Singapore, he worked at the Structural Biology Laboratory in York, UK. He obtained his undergraduate degree at the Indian Institute of Technology, India and his D. Phil at the University of York.



Website: www.bii.a-star.edu.sg/research/biography/chandra.php

PART I MODERATOR AND PANELIST



Dr. David M. Epstein, is the Associate Professor, Associate Dean and Director of the Centre for Technology & Development (CTeD) at Duke-NUS Graduate Medical School in Singapore. Dr. Epstein has over 20 years of global experience funding, managing and leading research organisations in early-stage, mid-size biotechnology, and multinational organisations. Through CTeD, he is leading the commercialisation of Duke-NUS intellectual property through organic growth & entrepreneurship in Singapore, and innovation globally. He co-founded the aptamer therapeutics company Archemix Corp where he developed ARC127 (Fovista™) now in late-stage clinical development for wet-

AMD, and ARC1905 (anti-C5) in development for dry-AMD at Ophthotech. Prior to joining the faculty at Duke-NUS, David was the Site-Head, Sr. Vice President and Chief Scientific Officer for OSI Pharmaceuticals, where he lead cancer drug discovery efforts conducted by over 140 scientists, and OSI's clinical-translational research effort on Tarceva™.

Mr. Yutaka Hishiyama has been serving at the Japan Agency for Medical Research and Development, called AMED, since April 1, 2015 on the day of the establishment. Before assuming to the Senior Director of AMED, he worked at the Office of the Healthcare Policy, the Secretariat of the Cabinet and participated in the process of the establishment of AMED. He is in charge of all the research and development projects funded by AMED.



A main role of AMED is to promote, support and accelerate medical research and development comprehensively, through funding, from basic research to clinical research. It is attempting to establish, maintain, and provide funding for promotion of research and development and for improvement of an environment for integrated research and development. It started strong management of all research and development programs by program directors, program supervisors and program officers. Through these projects AMED is promoting to make bridges between academia and industry.

He had been working at the Ministry of Education, Culture, Sports, Science and Technology for a long time and was involved in life science and bioethics policy regarding brain science, regenerative medicine, genome analysis, translational research and so on.



Dr. Taslimarif Saiyed is the Director and COO of C-CAMP, Centre for Cellular and Molecular Platforms. In this role, he manages C-CAMP's technology platforms, growth strategies, strategic collaborations for new technology creation, education and training programmes, business and innovation accelerator unit. He also oversees the Intellectual Property and Technology Transfer Office at C-CAMP.

Prior to joining C-CAMP, he worked as a Scientist with University of California, San Francisco (UCSF), studying neurodegenerative diseases like Parkinson's disease. He holds a doctorate in Neuroscience from Max-Planck Institute for Brain Research, Germany.

In the bay area, he also served as a Management Consultant with QB3 New Biotech Venture Consulting as well as in an individual capacity where he consulted for biotech firms in the US.

Dr. Pauline Tay manages the Innovation and Enterprise Directorate at the National Research Foundation (NRF) of the Prime Minister's Office of Singapore, formulating and implementing strategies to catalyse innovation and technology commercialisation across research, innovation and entrepreneurship ecosystems. Prior to this, Dr. Tay headed the Healthcare cluster at Intellectual Property Intermediary (IPI) for 4 years, providing technology sourcing and due diligence services to industry. With a PhD in Stem Cell Biology, and 8 years of R&D experience in a start-up, overseas university (Osaka School of Medicine) and government research institute (Institute of Medical Biology), Dr. Tay has an extensive network with local and overseas research, technology and enterprise communities. Before that, she started her career as a training consultant at the Singapore Productivity and Standards Board (PSB), followed by another 3 years of research administration at the Agency for Science, Technology and Research (A*STAR).



Dr. Christine Williams heads DSITI's Science Division. The Division, in close collaboration with the Queensland Chief Scientist, provides strategic leadership for the government's investment in science and research and develops Queensland Government science policy. The Division also provides scientific and technical advice and services to government agencies across the natural resources and environment spectrum that underpin their decision-making and legislative responsibilities.

Christine works in close partnership with other government agencies (state and federal), universities and other research groups, as well as natural resource management groups and industry. Christine is currently focussed on harnessing the opportunities provided by the



Advance Queensland initiative to attract and retain world class research and scientific talent to Queensland and grow the jobs of the future.

Prior to her current position, held since March 2007, Christine held a number of senior positions in Queensland Treasury, including Director of Economic Policy and Assistant Government Statistician (Economics). She was previously an academic at Queensland University of Technology and the University of Queensland where she taught statistics and econometrics. Christine is an economist with a Doctor of Philosophy from the University of Queensland and a Master of Philosophy from Oxford University.

Mr. Jee Young Yoon is a research staff and head of the industry analysis team at Korea Health Industry Development Institute (KHIDI) - a public agency under the Korean Ministry of Health & Welfare. He has been undertaking policy researches for pharmaceutical & medical technologies and industries, and is involved in formulating plans and ideas for government measures to help overall healthcare industries in Korea.



He has also been involved in devising several government plans for advancing pharmaceutical and other healthcare businesses; writing proposals for tax law amendment for healthcare SME's benefit, and creating public investment funds for the pharmaceutical sectors.

His past experiences in the steel-making (POSCO) and Information Technology (Korea Telecom) sectors, which are matured industries, has inspired him to apply his knowledge of various business best practices into the healthcare policy sector - which is a relatively growing industry in Korea.



Mr. Yoon graduated with a Bachelor of Arts in Sociology and Masters of Business Administration and ABD from Yonsei University, Korea.

PART II MODERATOR AND PANELIST



Dr. Ken Noonan is Chief Executive Officer, Lightstone Singapore Pte. Ltd (LSV(SG)) an early stage venture fund focused on life science technologies originating in or relocating to Singapore. Previously Ken was a senior partner and head of the European Life Sciences practice at L.E.K. Consulting LLP, a global management firm. Dr Noonan completed his Ph.D. in Biochemistry from Princeton University.

Dr. Philippe Buchy is a Medical Doctor with a specialization in Clinical Pathology, and holds a PhD in virology. He worked for 16 years with the Pasteur Institute as a Virologist and headed several National or WHO reference centres on influenza, H5N1, rabies and arboviruses. He authored over 140 publications in peer-reviewed journals (Science, Nature, PNAS, Emerging Infectious Diseases, Lancet, etc.) as well as several book chapters and WHO guidelines. He was awarded the International Mérieux Price in 2014 in recognition of his research on infectious diseases in developing countries. In June 2014, he joined GSK vaccines as Director of Scientific Affairs and Public Health in Asia-Pacific region.



Mr. Luigi Ricciardi is the CEO of Menarini Biomarkers Singapore - responsible for managing the operation of Menarini Biomarker Singapore, and to spearhead Menarini's research efforts internationally. He joined Menarini Biomarkers Singapore in 2014. From 2007 to 2012, he was the Founder and Director of the Industrial Development Group (IDG) for the Biomedical Research Council (BMRC-A-STAR).

Luigi was the Founder and General Manager of Biopolo Scrl, a technology transfer company in Italy from 1995 to 2007. He focused on the area of technology transfer and start up creation. His main achievements include the feasibility study and start-up of four MBOs from multinational pharmaceutical companies (Biosearch Italia, Novuspharma, Newron, BioXell). The four Newcos went through successful IPOs at Nuovo Mercato and Swiss Stock Exchange.

Luigi holds a Degree in Nuclear Engineering from the University of Pisa. He has been on the Euratom Fellowship in the Centre Energie Nucléaire, Mol in Belgium. He also holds a Master of Business and Administration Degree from the University of L. Bocconi in Italy.

Mr. Dong Wu is the Head of Johnson & Johnson Innovation, Asia Pacific. Dong joined the Innovation team from Johnson & Johnson's Consumer business where he was Vice President of R&D, responsible for the Global Engineering Organization and leading the transformation of the emerging markets R&D groups. Dong joined Johnson & Johnson as the Head of Emerging Markets R&D where he focused on developing personal care products for emerging markets. Dong facilitated programs aimed at developing high value products and driving a culture of innovation. Dong has a Bachelor of Science degree from Fudan University and a MBA from China Europe International Business School.





SciCafe

Nature SciCafe Asia

— Biotech Science & Investment Forum —

PIGEONHOLE LIVE

This year, we have engaged Pigeonhole Live, an interactive Q&A platform to create a more dynamic session for our attendees.

With this platform, you can post questions to the speakers and panelists, and vote for questions that others have asked - all by using your mobile, tablet or laptops.


Here's how to get started.

STEP 1: Go to www.pigeonhole.at

STEP 2: Enter the event passcode - **NSCA2016**

STEP 3: Enter the session

STEP 4: Start posting your questions or like what others have posted. Questions with more likes will automatically move up the list.



WIFI

For those coming from overseas, wifi will be available for you. Please enquire from the staff when you register at the event.



SciCafe

Nature SciCafe Asia

— Biotech Science & Investment Forum —

— Organisers —



nature
biotechnology

— Partner —

NUHS

National University
Health System

— Supporters —

NATIONAL RESEARCH FOUNDATION
PRIME MINISTER'S OFFICE
SINGAPORE



BIOMARKERS
S I N G A P O R E

Johnson & Johnson INNOVATION